BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 30521671)

  • 1. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
    Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
    Mittermeier T; Farrant C; Wise MR
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Romero SA; Young K; Hickey M; Su HI
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Dominick S; Hickey M; Chin J; Su HI
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
    Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009458. PubMed ID: 23737032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby A; Hussain M; Rishworth JR; Rees MC
    Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).
    Sangkomkamhang US; Lumbiganon P; Pattanittum P
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD008994. PubMed ID: 33226133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Bofill Rodriguez M; Lethaby A; Jordan V
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD002126. PubMed ID: 32529637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery versus medical therapy for heavy menstrual bleeding.
    Marjoribanks J; Lethaby A; Farquhar C
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD003855. PubMed ID: 26820670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby AE; Cooke I; Rees M
    Cochrane Database Syst Rev; 2005 Oct; (4):CD002126. PubMed ID: 16235297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclical progestogens for heavy menstrual bleeding.
    Bofill Rodriguez M; Lethaby A; Low C; Cameron IT
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD001016. PubMed ID: 31425626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials.
    Abu Hashim H; Ghayaty E; El Rakhawy M
    Am J Obstet Gynecol; 2015 Oct; 213(4):469-78. PubMed ID: 25797236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin for endometrial hyperplasia.
    Shiwani H; Clement NS; Daniels JP; Atiomo W
    Cochrane Database Syst Rev; 2024 May; 5(5):CD012214. PubMed ID: 38695827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin for endometrial hyperplasia.
    Clement NS; Oliver TR; Shiwani H; Sanner JR; Mulvaney CA; Atiomo W
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012214. PubMed ID: 29077194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.
    Wan YL; Holland C
    Climacteric; 2011 Dec; 14(6):622-32. PubMed ID: 22017273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
    Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
    Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
    Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.